Loading clinical trials...

Survey Study for Velaglucerase Alfa (VPRIV) in Japan | Clinical Trials | Clareo Health

COMPLETED

Survey Study for Velaglucerase Alfa (VPRIV) in Japan

VPRIV Drug Use-Result Survey (Japan)

NCT03625882•Takeda

Summary

The objective of this post-marketing survey study is to collect data to determine the safety and efficacy of velaglucerase alfa (VPRIV) in participants with Gaucher disease who are new to therapy or have been switched from another therapeutic agent for Gaucher disease.

Eligibility

Age

All ages

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Male or female participants with a confirmed diagnosis of Gaucher disease
•Participants who are either naïve to treatment or participants that have been treated with another therapeutic agent for Gaucher disease
•Participants who start VPRIV treatment or transition from VPRIV clinical studies during the enrollment period

Exclusion Criteria

•\-

Locations (35)

Konan

Kōnan, Aichi-ken, Japan

Nagoya

Nagoya, Aichi-ken, Japan

Kitakyushu

Kitakyushu, Fukuoka, Japan

Kurume

Kurume, Fukuoka, Japan

Fukuyama

Fukuyama, Hiroshima, Japan

Higashihiroshima

Higashihiroshima, Hiroshima, Japan

Obihiro

Obihiro, Hokkaido, Japan

Sagamihara

Sagamihara, Kanagawa, Japan

Sendai

Sendai, Miyagi, Japan

Suita

Suita, Osaka, Japan

Key Dates

Start Date

September 2, 2014

Primary Completion Date

May 14, 2024

Completion Date

May 14, 2024

Last Updated

March 4, 2026

Enrollment

ACTUAL participants

Conditions

Gaucher Disease

GammaGA: Prevalence of Acid Sphingomyelinase Deficiency Disease (ASMD) and Gaucher Disease in Patients With Monoclonal Gammopathies and/or Multiple Myeloma

NCT05992532

Gaucher DiseaseAcid SphingoMyelinase Deficiency

View study

RECRUITING

Institutional Registry of Rare Diseases

NCT06573723

Rare DiseasesAmyloidosis+24 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 4, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Survey Study for Velaglucerase Alfa (VPRIV) in Japan

Inclusion Criteria

Exclusion Criteria

GammaGA: Prevalence of Acid Sphingomyelinase Deficiency Disease (ASMD) and Gaucher Disease in Patients With Monoclonal Gammopathies and/or Multiple Myeloma

Institutional Registry of Rare Diseases

A Clinical Trial of PR001 (LY3884961) in Patients With Peripheral Manifestations of Gaucher Disease (PROCEED)

A Long-term Follow-up Study of Gaucher Disease

A Study Measuring Substances Potentially Indicating Bone Problems in Adults With Type 1 Gaucher Condition

A Study of Enzyme Replacement Therapy (VPRIV) in People With Type 1 Gaucher Disease Who Were Previously Treated With Substrate Reduction Therapy